نمایش مختصر رکورد

dc.date.accessioned1399-07-08T18:11:42Zfa_IR
dc.date.accessioned2020-09-29T18:11:42Z
dc.date.available1399-07-08T18:11:42Zfa_IR
dc.date.available2020-09-29T18:11:42Z
dc.date.issued2015-12-01en_US
dc.date.issued1394-09-10fa_IR
dc.identifier.citation(2015). Seven-Day Bismuth-based Quadruple Therapy as an Initial Treatment for Helicobacter pylori Infection in a High Metronidazole Resistant Area. Asian Pacific Journal of Cancer Prevention, 16(14), 6089-6092.en_US
dc.identifier.issn1513-7368
dc.identifier.issn2476-762X
dc.identifier.urihttp://journal.waocp.org/article_31375.html
dc.identifier.urihttps://iranjournals.nlai.ir/handle/123456789/38385
dc.description.abstract<b>Background:</b> The prevalence of metronidazole-resistant H. pylori is almost 50% in Thailand which severelylimits the use of this drug for eradication therapy. The aims of this study were to evaluate the efficacy andsafety profiles of 7-day bismuth-based quadruple therapy including metronidazole as an initial treatment for H.pylori infection in a high metronidazole resistance area. Materials and <br/><b>Methods</b>: This study was performed atThammasat University Hospital and King Chulalongkorn Memorial Hospital during January 2009 to October2010. Patients with non-ulcer dyspepsia (NUD) with active H. pylori infection were assigned to receive sevendays of quadruple therapy (pantoprazole 40 mg bid, bismuth subsalicylate 1,048 mg bid, amoxicillin 1 gm bidand metronidazole 400 mg tid). H. pylori infection was defined as positive H. pylori culture or two positive tests(rapid urease test and histology). Antibiotic susceptibility test for metronidazole by Epsilometer test (E-test)was performed in all positive cultures. At least four weeks after treatment, 13C urea breath test (13C-UBT) wasperformed to confirm H. pylori eradication. <br/><b>Results</b>: A total of 114 patients were enrolled in this study, 50 malesand 64 females with a mean age of 49.8 years. All 114 patients had a diagnosis of NUD. Overall eradication asconfirmed by negative 13C-UBT was achieved in 94 out of 114 patients (82.5%). 44 patients had positive culturesand success for E-test. In vitro metronidazole resistance was observed in 22/44 (50%) patients. Eradication rate inpatients with metronidazole resistant strains was 16/22 (72.7%) and 20/22 (90.1%) with metronidazole sensitivestrains (72.7% vs 90.1%, p-value=0.12; OR=3.75 [95%CI=0.6-31.5]). Minor adverse reactions included nausea,bitter taste, diarrhea and black stools but none of the patients dropped out from the study. <br/><b>Conclusions</b>: Initialtreatment with 7-day bismuth-based quadruple therapy including metronidazole, amoxycillin and pantoprazoleis highly effective and well tolerated for metronidazole-sensitive H. pylori infections. However, the efficacymarkedly decline with metronidazole resistance. Longer duration of this regimen might be required to improvethe eradication rate and larger multi-center studies are needed to confirm this hypothesis.en_US
dc.format.extent414
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoen_US
dc.publisherWest Asia Organization for Cancer Prevention (WAOCP)en_US
dc.relation.ispartofAsian Pacific Journal of Cancer Preventionen_US
dc.subjectBismuthen_US
dc.subjectquadruple therapyen_US
dc.subjectHelicobacter pylori eradicationen_US
dc.subjectThailanden_US
dc.titleSeven-Day Bismuth-based Quadruple Therapy as an Initial Treatment for Helicobacter pylori Infection in a High Metronidazole Resistant Areaen_US
dc.typeTexten_US
dc.citation.volume16
dc.citation.issue14
dc.citation.spage6089
dc.citation.epage6092


فایل‌های این مورد

Thumbnail

این مورد در مجموعه‌های زیر وجود دارد:

نمایش مختصر رکورد